

ASSIGNMENT - WORLDWIDE

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each undersigned inventor (hereinafter referred to singly and collectively as "ASSIGNOR") has sold, assigned, and transferred, and hereby sells, assigns, and transfers, unto

bluebird bio, Inc.
455 Grand Union Boulevard
Somerville, Massachusetts 02145
United States of America

(hereinafter referred to as "ASSIGNEE") its successors and assigns, the full and exclusive right, title and interest for the United States, its territories and possessions, and all foreign countries in and to this invention relating to

MUC16 CHIMERIC ANTIGEN RECEPTORS

as set forth in the following Patent Applications:

United States Provisional Application No. 63/298,141, filed January 10, 2022; and

U.S. International Application No. PCT/US2023/10518, filed January 10, 2023, which claims the benefit of United States Provisional Application No. 63/298,141, filed January 10, 2022;

including (a) all other applications for Letters Patent of the United States and countries foreign thereto for above-identified invention or inventions, (b) all Letters Patent which may issue from said applications in the United States and countries foreign thereto, (c) all divisions, continuations, reissues, and extensions of said applications and Letters Patent, and (d) the right to claim for any of said applications the full benefits and priority rights under the International Convention and any other international agreement to which the United States adheres; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.

ASSIGNOR HEREBY AUTHORIZES ASSIGNEE to file patent applications in any or all countries on the above-identified invention or inventions in the name of the undersigned or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable under the International Convention or otherwise.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.


ASSIGNOR HEREBY AGREES (a) to communicate to ASSIGNEE, its successors and assigns, or their representative or agents, all facts and information known or available to ASSIGNOR respecting said invention or inventions, including evidence for interference, reexamination, reissue, opposition, revocation, extension, or infringement purposes or other legal, judicial, or administrative proceedings, whenever requested by ASSIGNEE; (b) to testify in person or by affidavit as required by ASSIGNEE, its successors and assigns, in any such proceeding in the United States or a country foreign thereto; (c) to execute and deliver, upon request by ASSIGNEE, all lawful papers including, but not limited to, original, divisional, continuation, and reissue applications, renewals, assignments, powers of attorney, oaths, affidavits, and declarations, depositions; and (d) to provide all reasonable assistance to ASSIGNEE, its successors and assigns, in obtaining and enforcing proper title in and protection for said invention or inventions under the intellectual property laws of the United States and countries foreign thereto.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.

ASSIGNOR HEREBY GRANTS to the law firm of **McCarter & English, LLP** the power and authority to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

ASSIGNOR UNDERSTANDS AND AGREES that the attorneys and agents of the law firm of **McCarter & English, LLP** do not personally represent ASSIGNOR OR ASSIGNOR's legal interests; since said attorneys and agents cannot provide legal advice to ASSIGNOR with respect to this Assignment, ASSIGNOR acknowledges its right to seek its own independent legal counsel.

Executed this 25th day of January, 2023 
Tina ALBERSHARDT

Witness Signature: 

Date: 25 January 2023

Witness Printed Name: Kristina Malan

ASSIGNEE acceptance:

Executed this 2 day of May, 2023

By: 

Name: Andrew Obenshain

Title: CEO

Company: bluebird bio, Inc.

Witness Signature: 

Date: 5/2/2023

Witness Printed Name: Maura McGovern

ASSIGNMENT - WORLDWIDE

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each undersigned inventor (hereinafter referred to singly and collectively as "ASSIGNOR") has sold, assigned, and transferred, and hereby sells, assigns, and transfers, unto

bluebird bio, Inc.
455 Grand Union Boulevard
Somerville, Massachusetts 02145
United States of America

(hereinafter referred to as "ASSIGNEE") its successors and assigns, the full and exclusive right, title and interest for the United States, its territories and possessions, and all foreign countries in and to this invention relating to

MUC16 CHIMERIC ANTIGEN RECEPTORS

as set forth in the following Patent Applications:

U.S. International Application No. PCT/US2023/10518, filed January 10, 2023, which claims the benefit of United States Provisional Application No. 63/298,141, filed January 10, 2022;

including (a) all other applications for Letters Patent of the United States and countries foreign thereto for above-identified invention or inventions, (b) all Letters Patent which may issue from said applications in the United States and countries foreign thereto, (c) all divisions, continuations, reissues, and extensions of said applications and Letters Patent, and (d) the right to claim for any of said applications the full benefits and priority rights under the International Convention and any other international agreement to which the United States adheres; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.

ASSIGNOR HEREBY AUTHORIZES ASSIGNEE to file patent applications in any or all countries on the above-identified invention or inventions in the name of the undersigned or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable under the International Convention or otherwise.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.

ASSIGNOR HEREBY AGREES (a) to communicate to ASSIGNEE, its successors and assigns, or their representative or agents, all facts and information known or available to ASSIGNOR respecting said invention or inventions, including evidence for interference, reexamination, reissue, opposition, revocation, extension, or infringement purposes or other legal, judicial, or administrative proceedings, whenever requested by ASSIGNEE; (b) to testify in person or by affidavit as required by ASSIGNEE, its successors and assigns, in any such proceeding in the United States or a country foreign thereto; (c) to execute and deliver, upon request by ASSIGNEE, all lawful papers including, but not limited to, original, divisional, continuation, and reissue applications, renewals, assignments, powers of attorney, oaths, affidavits, and declarations, depositions; and (d) to provide all reasonable assistance to ASSIGNEE, its successors and assigns, in obtaining and enforcing proper title in and protection for said invention or inventions under the intellectual property laws of the United States and countries foreign thereto.


ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.

ASSIGNOR HEREBY GRANTS to the law firm of **McCarter & English, LLP** the power and authority to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

ASSIGNOR UNDERSTANDS AND AGREES that the attorneys and agents of the law firm of **McCarter & English, LLP** do not personally represent ASSIGNOR OR ASSIGNOR's legal interests; since said attorneys and agents cannot provide legal advice to ASSIGNOR with respect to this Assignment, ASSIGNOR acknowledges its right to seek its own independent legal counsel.

Executed this 26th day of January, 2023


Geoffrey Blackburn PARSONS


Witness Signature: 

Date: 1/26/2023

Witness Printed Name: Yuko Soneoka Gee.

ASSIGNEE acceptance:


Executed this 2 day of May, 2023

By: 

Name: Andrew Obenshain

Title: CEO

Company: bluebird bio, Inc.

Witness Signature: 

Date: 5/2/2023

Witness Printed Name: Maureen McGovern

ASSIGNMENT - WORLDWIDE

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each undersigned inventor (hereinafter referred to singly and collectively as "ASSIGNOR") has sold, assigned, and transferred, and hereby sells, assigns, and transfers, unto

2seventy bio, Inc.
60 Binney Street
Cambridge, Massachusetts 02142
United States of America

(hereinafter referred to as "ASSIGNEE") its successors and assigns, the full and exclusive right, title and interest for the United States, its territories and possessions, and all foreign countries in and to this invention relating to

MUC16 CHIMERIC ANTIGEN RECEPTORS

as set forth in the following Patent Applications:

United States Provisional Application No. 63/298,141, filed January 10, 2022; and

U.S. International Application No. PCT/US2023/10518, filed January 10, 2023, which claims the benefit of United States Provisional Application No. 63/298,141, filed January 10, 2022;

including (a) all other applications for Letters Patent of the United States and countries foreign thereto for above-identified invention or inventions, (b) all Letters Patent which may issue from said applications in the United States and countries foreign thereto, (c) all divisions, continuations, reissues, and extensions of said applications and Letters Patent, and (d) the right to claim for any of said applications the full benefits and priority rights under the International Convention and any other international agreement to which the United States adheres; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.

ASSIGNOR HEREBY AUTHORIZES ASSIGNEE to file patent applications in any or all countries on the above-identified invention or inventions in the name of the undersigned or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable under the International Convention or otherwise.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.

ASSIGNOR HEREBY AGREES (a) to communicate to ASSIGNEE, its successors and assigns, or their representative or agents, all facts and information known or available to ASSIGNOR respecting said invention or inventions, including evidence for interference, reexamination, reissue, opposition, revocation, extension, or infringement purposes or other legal, judicial, or administrative proceedings, whenever requested by ASSIGNEE; (b) to testify in person or by affidavit as required by ASSIGNEE, its successors and assigns, in any such proceeding in the United States or a country foreign thereto; (c) to execute and deliver, upon request by ASSIGNEE, all lawful papers including, but not limited to, original, divisional, continuation, and reissue applications, renewals, assignments, powers of attorney, oaths, affidavits, and declarations, depositions; and (d) to provide all reasonable assistance to ASSIGNEE, its successors and assigns, in obtaining and enforcing proper title in and protection for said invention or inventions under the intellectual property laws of the United States and countries foreign thereto.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.

ASSIGNOR HEREBY GRANTS to the law firm of **McCarter & English, LLP** the power and authority to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

ASSIGNOR UNDERSTANDS AND AGREES that the attorneys and agents of the law firm of **McCarter & English, LLP** do not personally represent ASSIGNOR OR ASSIGNOR's legal interests, but instead represent the interests of ASSIGNEE; since said attorneys and agents cannot provide legal advice to ASSIGNOR with respect to this Assignment, ASSIGNOR acknowledges its right to seek its own independent legal counsel.


Executed this 2 day of May, 2023

By: 

Name: Andrew Obenshain

Title: CEO

Company: bluebird bio, Inc.

Witness Signature: 

Date: 5/2/2023

Witness Printed Name: Maura McGovern

ASSIGNEE acceptance:


Executed this 1st day of June, 2023

By: 

Name: Adam Gastonguay

Title: Director of Intellectual Property

Company: 2seventy bio, Inc.

Witness Signature: 

Date: 01 Jun 2023

Witness Printed Name: Courtney Gastonguay

PATENT ASSIGNMENT AGREEMENT

This Patent Assignment Agreement (this “**Assignment**”) is entered into effective as of April 1, 2024 by and between 2seventy bio, Inc., a Delaware corporation (“**Assignor**”), and Regeneron Pharmaceuticals, Inc., a New York corporation (“**Assignee**”, together with Assignor, the “**Parties**”). Capitalized terms used but not defined herein have the meanings ascribed to such terms in the Asset Purchase Agreement (defined below).

WHEREAS, Assignor and Assignee have entered into that certain Asset Purchase Agreement, dated as of January 29, 2024 (as may be amended or restated from time to time, the “**Asset Purchase Agreement**”), pursuant to which Assignor has agreed to, among other things, sell, assign, transfer, convey, and deliver to Assignee certain Intellectual Property, as more fully described in the Asset Purchase Agreement, on the terms and subject to the conditions set forth in the Asset Purchase Agreement; and

WHEREAS, such Intellectual Property includes, without limitation, the Patents set forth on Annex A hereto (collectively, the “**Transferred Patents**”).

NOW, THEREFORE, pursuant to the Asset Purchase Agreement, and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

1. Assignment. Assignor hereby sells, assigns, transfers and delivers to Assignee, and Assignee hereby purchases and acquires from Assignor, all rights, titles, and interests of Assignor in, to and under the Transferred Patents in the United States and in all foreign countries (including, without limitation, all rights therein provided by international conventions and treaties), including, without limitation, any priority applications, applications for patent, patents, reissues, divisions, continuations, continuations-in-part, extensions, re-examinations and foreign equivalents thereof, all rights to claim priority thereto or therefrom, and all rights therein provided by international treaties and conventions, together with all associated income, royalties, damages or payments accrued, due or payable as of the Effective Date or thereafter and including, without limitation, all claims for damages by reason of past, present or future infringement or other unauthorized use of the Transferred Patents, with the right to sue for, and collect the same, in each case, for Assignee’s own use and enjoyment, and for the use and enjoyment of its successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment and sale had not been made. Assignee acknowledges that Assignor makes no representations or warranties with respect to the Transferred Patents except as specifically set forth in the Asset Purchase Agreement.

2. Recordation. Assignor hereby authorizes and requests that the United States Patent and Trademark Office Commissioner for Patents (the “**USPTO**”) and any other applicable Governmental Authority or registrar (including any applicable foreign or international office or registrar) record this Assignment and record Assignee as the assignee and owner of the Transferred Patents. Assignor further authorizes and requests the USPTO and any other applicable Governmental Authority or registrar (including any applicable foreign or international office or registrar) to transfer all registrations and registration applications included in the Transferred Patents to Assignee as purchaser of Assignor’s rights, titles and interests therein, in accordance with this Assignment, and to issue to Assignee all registrations that may issue with respect to any applications for registration of patent rights included in such Transferred Patents.

3. Further Assurances.

3.1 Upon Assignee's reasonable request and without further compensation, Assignor shall execute, acknowledge and deliver all such other instruments and documents and shall take all such other actions reasonably necessary or required by Law to consummate and make fully effective the transaction contemplated by this Assignment.

3.2 If Assignee is unable for any reason to secure any of Assignor's signatures to any document required to file, prosecute, register or memorialize the assignment of any rights under any Transferred Patents as provided under this Assignment, then Assignor hereby irrevocably designates and appoints Assignee and Assignee's duly authorized officers and agents as Assignor's agents and attorneys-in-fact to act for and on each of Assignor's behalf and instead of Assignor to take all lawfully permitted acts to further the filing, prosecution, registration, memorialization of assignment, issuance, and enforcement of rights under such Transferred Patents, all with the same legal force and effect as if executed by Assignor. The foregoing is deemed a power coupled with an interest and is irrevocable.

4. No Third-Party Beneficiaries. Nothing in this Assignment, express or implied, is intended or shall be construed to confer upon, or to give to, any Person other than Assignee and its successors and assigns any remedy or claim under or by reason of this Assignment or any terms, covenants or conditions hereof, and all the terms, covenants and conditions, promises and agreements in this Assignment contained shall be for the sole and exclusive benefit of Assignee and its respective successors and assigns.

5. Interpretation. This Assignment is intended to implement the provisions of the Asset Purchase Agreement, is expressly subject to the terms and conditions thereof, and shall not be construed to enhance, extend or limit the representations and warranties, rights, obligations or remedies of either Party. In case of any conflict or inconsistency between the terms and conditions of this Assignment and the terms and conditions of the Asset Purchase Agreement, the terms and conditions of the Asset Purchase Agreement shall govern.

6. Amendment. Except as otherwise provided herein, no amendment, modification or supplement of any provision of this Assignment shall be valid or effective unless made in writing and signed by a duly authorized officer of each Party.

7. Waiver. No provision of this Assignment shall be waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party.

8. Governing Law. This Assignment shall be governed and construed in accordance with the Laws of the State of Delaware, without giving effect to any choice of law provisions thereof that would result in the application of the Law of any jurisdiction other than Delaware. The Parties hereby irrevocably submit to the exclusive jurisdiction of the Court of Chancery of the State of Delaware sitting in the New Castle County (or, only if the Court of Chancery of the State of Delaware declines to accept or does not have jurisdiction over a particular matter, any federal or other state court sitting in New Castle County within the State of Delaware), and the appellate courts having jurisdiction of appeals in such courts, in each case, over any dispute arising under this Assignment and each Party hereby irrevocably agrees that all claims in respect of this Assignment shall be heard and determined in such courts. The Parties hereby irrevocably waive, to the fullest extent permitted by applicable Law, any objection which they may now or hereafter have to the laying of venue of any such claim brought in such court or any defense of inconvenient forum for the

maintenance of such claim. Each of the Parties agrees that a judgment in any such dispute may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law.

9. Counterparts. This Agreement may be executed in one or more counterparts, and signature pages may be delivered by portable document format (PDF), DocuSign or any other electronic signature complying with the U.S. federal ESIGN Act of 2000, the Delaware Uniform Electronic Transactions Act, and any other applicable Law, each of which shall be deemed an original, but all of which will be considered one and the same agreement and will become effective when one or more counterparts have been signed by each of the Parties and delivered to the other Party, it being understood that all Parties need not sign the same counterpart.

[Signature page follows]

IN WITNESS WHEREOF, Assignor intending to be legally bound has caused this Assignment to be executed by its duly authorized representatives as of the Effective Date.

ASSIGNOR:

2SEVENTY BIO, INC.

By: _____

Name: Nick Leschly

Title: President and Chief Executive Officer

Witness:

Ana Fernandez 03-19-24
Name and date

Witness:


[Signature] 3-19-24
Name and date

COMMONWEALTH OF
Massachusetts)

) SS.

COUNTY OF
Middlesex)

On this 1st day of March, 2024, there appeared before me Nick Leschly
personally known to me, who acknowledged that he/she signed the foregoing Assignment as
his/her voluntary act and deed on behalf and with full authority of 2seventy bio, Inc.



Kelley J. Dolliver
Notary Public

[Signature Page to Patent Assignment Agreement]

IN WITNESS WHEREOF, Assignee intending to be legally bound has caused this Assignment to be executed by its duly authorized representatives as of the Effective Date.

ASSIGNEE:


REGENERON PHARMACEUTICALS, INC.

By: 

Name: Nouhad Hussein

Title: Senior Vice President, Head of Business
Development and Corporate Strategy

Witness: Paige Cooperman

 3/11/2024
Name and date

Witness: Victoria A. Thiele - Gambino

 3/11/2024
Name and date

STATE OF New York)

) SS.

COUNTY OF Westchester)

On this 11th day of March, 2024, there appeared before me Nouhad Hussein, personally known to me, who acknowledged that he/she signed the foregoing Assignment as his/her voluntary act and deed on behalf and with full authority of Regeneron Pharmaceuticals, Inc.

NANCY FERRARA
NOTARY PUBLIC, STATE OF NEW YORK
NO. 03-4823560
QUALIFIED IN WESTCHESTER COUNTY
COMMISSION EXPIRES JUNE 30, 2027


Notary Public

[Signature Page to Patent Assignment Agreement]

Exhibit A

Transferred Patents

Zseventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-036AU	Owned by Zseventy	AU	2014296626	2014296626	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	01/27/2016	06/20/2019	GRANTED	07/23/2034
BLUE-036AU2	Owned by Zseventy	AU	2019203955	2019203955	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	06/06/2019	06/10/2021	GRANTED	07/23/2034
BLUE-036BE	Owned by Zseventy	BE	14832043.5	3027204	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	02/23/2016	01/05/2022	GRANTED	07/23/2034
BLUE-036C1	Owned by Zseventy	US	16/219640	US 2019-0112372 A1	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	12/13/2018	10/29/2019	GRANTED	07/23/2034
BLUE-036C2	Owned by Zseventy	US	16/540673	US 2020-0071399 A1	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	08/14/2019		ABANDONED	
BLUE-036C3	Owned by Zseventy	US	16/573254	US-2020-0071401-A1	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	09/17/2019	12/20/2022	GRANTED	07/25/2035
BLUE-036C4	Owned by Zseventy	US	17/675246		MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	02/18/2022		ABANDONED	
BLUE-036CA	Owned by Zseventy	CA	2956667	2956667	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	01/27/2017		PUBLISHED	
BLUE-036CH	Owned by Zseventy	CH	14832043.5	3027204	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	02/23/2016	01/05/2022	GRANTED	07/23/2034
BLUE-036CIP	Owned by Zseventy	US	14/608098	US 2015-0266973 A1	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	01/28/2015	10/01/2019	GRANTED	07/23/2034
BLUE-036D1	Owned by Zseventy	US	19/054223	US-2023-0287111-A1	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	11/10/2022		PUBLISHED	
BLUE-036DE	Owned by Zseventy	DE	14832043.5	3027204	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	02/23/2016	01/05/2022	GRANTED	07/23/2034
BLUE-036DK	Owned by Zseventy	DK	14832043.5	3027204	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	02/23/2016	01/05/2022	GRANTED	07/23/2034
BLUE-036EP	Owned by Zseventy	EP	14832043.5	3027204	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	02/23/2016	01/05/2022	GRANTED	07/23/2034
BLUE-036EP2	Owned by Zseventy	EP	21162954.8	3925618	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	03/16/2021		PUBLISHED	
BLUE-036ES	Owned by Zseventy	ES	14832043.5	3027204	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	02/23/2016	01/05/2022	GRANTED	07/23/2034
BLUE-036FR	Owned by Zseventy	FR	14832043.5	3027204	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	02/23/2016	01/05/2022	GRANTED	07/23/2034
BLUE-036GB	Owned by Zseventy	GB	14832043.5	3027204	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	02/23/2016	01/05/2022	GRANTED	07/23/2034
BLUE-036HK	Owned by Zseventy	HK	16112493.9	1224194	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	10/31/2016	09/16/2022	GRANTED	07/23/2034
BLUE-036HK2	Owned by Zseventy	HK	42022055546.0	40066967 A	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	06/22/2022		PUBLISHED	07/23/2034
BLUE-036IE	Owned by Zseventy	IE	14832043.5	3027204	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	02/23/2016	01/05/2022	GRANTED	07/23/2034
BLUE-036IT	Owned by Zseventy	IT	14832043.5	3027204	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	02/23/2016	01/05/2022	GRANTED	07/23/2034
BLUE-036JP	Owned by Zseventy	JP	2016-531761	2016-531567	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	01/27/2016	06/21/2019	GRANTED	07/23/2034
BLUE-036JP2	Owned by Zseventy	JP	2019-112035	2019-146598	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	07/23/2014		ABANDONED	
BLUE-036JP3	Owned by Zseventy	JP	2020-92158		MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	05/27/2020	09/02/2020	GRANTED	07/23/2034
BLUE-036NL	Owned by Zseventy	NL	14832043.5	3027204	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	02/23/2016	01/05/2022	GRANTED	07/23/2034
BLUE-036P1	Owned by Zseventy	US	61/859697		MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	07/29/2013		CONV COMPLE	07/29/2014
BLUE-036P2	Owned by Zseventy	US	61/934092		MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	01/31/2014	01/31/2014		CONV COMPLE	01/31/2015
BLUE-036PC	Owned by Zseventy	WO	PCT/US2014/047852	WO 2015/017214	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	07/23/2014		COMPLETED	
BLUE-036USPC	Owned by Zseventy	US	14/908734	US 2016-0311901 A1	MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF	07/29/2013	01/29/2016	02/05/2019	GRANTED	07/23/2034
Zseventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-068AU	Owned by Zseventy	AU	2017250773	2017250773	SALVAGE CHIMERIC ANTIGEN RECEPTOR SYSTEMS	04/14/2016	10/17/2018		ABANDONED	
BLUE-068CA	Owned by Zseventy	CA	3020993	3020993	SALVAGE CHIMERIC ANTIGEN RECEPTOR SYSTEMS	04/14/2016	10/12/2018		PUBLISHED	
BLUE-068CN	Owned by Zseventy	CN	201780034987.0	109311963	SALVAGE CHIMERIC ANTIGEN RECEPTOR SYSTEMS	04/14/2016	12/05/2018		ABANDONED	
BLUE-068EP	Owned by Zseventy	EP	17783220.1	3443002	SALVAGE CHIMERIC ANTIGEN RECEPTOR SYSTEMS	04/14/2016	11/23/2018		PUBLISHED	
BLUE-068JP	Owned by Zseventy	JP	2018-554036	2019-518425	SALVAGE CHIMERIC ANTIGEN RECEPTOR SYSTEMS	04/14/2016	10/12/2018	08/16/2022	ALLOWED	04/14/2037
BLUE-068P1	Owned by Zseventy	US	62/322634		SALVAGE CHIMERIC ANTIGEN RECEPTOR SYSTEMS	04/14/2016	04/14/2016		CONV COMPLE	
BLUE-068P2	Owned by Zseventy	US	62/356335		SALVAGE CHIMERIC ANTIGEN RECEPTOR SYSTEMS	06/29/2016	06/29/2016		CONV COMPLE	
BLUE-068PC	Owned by Zseventy	WO	PCT/US2017/027606	WO 2017/180993	SALVAGE CHIMERIC ANTIGEN RECEPTOR SYSTEMS	04/14/2016	04/14/2017		COMPLETED	
BLUE-068USPC	Owned by Zseventy	US	16/092946	US-2022-0195039-A1	SALVAGE CHIMERIC ANTIGEN RECEPTOR SYSTEMS	04/14/2016	10/11/2018		PUBLISHED	
Zseventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-080.AT	Owned by Zseventy	AT	17872043.90	3541833	TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017		ALLOWED	
BLUE-080.AU	Owned by Zseventy	AU	2017362484.00		TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017	03/31/2022	GRANTED	11/16/2037
BLUE-080.AU2	Owned by Zseventy	AU	2022201775.00		TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017		PENDING	
BLUE-080.BE	Owned by Zseventy	BE	17872043.90	3541833	TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017		ALLOWED	11/16/2037
BLUE-080.BR	Owned by Zseventy	BR	BR1120190099042		TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017		PUBLISHED	
BLUE-080.C1	Owned by Zseventy	US	18/297491	US-2023-0364141	TGFBETA SIGNAL CONVERTOR	11/17/2016	04/07/2023		PUBLISHED	
BLUE-080.CA	Owned by Zseventy	CA	3043888.00	3043888	TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017		PUBLISHED	
BLUE-080.CH	Owned by Zseventy	CH	17872043.90	3541833	TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017		ALLOWED	11/16/2037
BLUE-080.CN	Owned by Zseventy	CN	201780077533.10	CN 110072885 A	TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017		ALLOWED	11/16/2037
BLUE-080.CN2	Owned by Zseventy	CN	202311619803.00		TGF BETA SIGNAL CONVERTOR	11/17/2016	11/30/2023		PENDING	
BLUE-080.DE	Owned by Zseventy	DE	17872043.90	3541833	TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017		ALLOWED	11/16/2037
BLUE-080.DK	Owned by Zseventy	DK	17872043.90	3541833	TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017		ALLOWED	11/16/2037
BLUE-080.EA	Owned by Zseventy	EA	201991186.00	201991186	TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017		GRANTED	11/16/2037
BLUE-080.EP	Owned by Zseventy	EP	17872043.90	3541833	TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017		ALLOWED; OPT OUT FILED	11/16/2037
BLUE-080.EP2	Owned by Zseventy	EP	23216595.10		TGF BETA SIGNAL CONVERTOR	11/17/2016	12/14/2023		PENDING	
BLUE-080.ES	Owned by Zseventy	ES	17872043.90	3541833	TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017		ALLOWED	11/16/2037
BLUE-080.FR	Owned by Zseventy	FR	17872043.90	3541833	TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017		ALLOWED	11/16/2037
BLUE-080.GB	Owned by Zseventy	GB	17872043.90	3541833	TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017		ALLOWED	11/15/2037
BLUE-080.HK	Owned by Zseventy	HK	19130700.80	40007184 A	TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017		PUBLISHED	
BLUE-080.IE	Owned by Zseventy	IE	17872043.90	3541833	TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017		ALLOWED	11/16/2037
BLUE-080.IL	Owned by Zseventy	IL	266628.00		TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017		ALLOWED	11/16/2037
BLUE-080.IL2	Owned by Zseventy	IL	309526.00		TGF BETA SIGNAL CONVERTOR	11/17/2016	12/19/2023		PENDING	
BLUE-080.IN	Owned by Zseventy	IN	201917022415.00	30/2019	TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017		PUBLISHED	
BLUE-080.IT	Owned by Zseventy	IT	17872043.90	3541833	TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017		ALLOWED	11/16/2037
BLUE-080.JP	Owned by Zseventy	JP	2019-526305	2019-535275	TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017	04/14/2023	GRANTED	11/16/2037
BLUE-080.JP2	Owned by Zseventy	JP	2023-64901	2023-89135	TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017		PUBLISHED	
BLUE-080.KR	Owned by Zseventy	KR	10-2019-7017172	10-2019-0077562	TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017		PUBLISHED	
BLUE-080.MX	Owned by Zseventy	MX	MX/a/2019/005724	TBA	TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017		PUBLISHED	
BLUE-080.NL	Owned by Zseventy	NL	17872043.90	3541833	TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017		ALLOWED	11/16/2037
BLUE-080.NZ	Owned by Zseventy	NZ	753521.00		TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017		PENDING	
BLUE-080.P1	Owned by Zseventy	US	62/423565		TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2016		EXPIRED	
BLUE-080.P2	Owned by Zseventy	US	62/467496		TGF BETA SIGNAL CONVERTOR	03/06/2017	03/06/2017		EXPIRED	
BLUE-080.PC	Owned by Zseventy	PCT	PCT/US17/62358	WO 2018/094244 A1	TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017		Nationalize	
BLUE-080.SE	Owned by Zseventy	SE	17872043.90	3541833	TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017		ALLOWED	11/16/2037
BLUE-080.SG	Owned by Zseventy	SG	112019043535		TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017		PENDING	
BLUE-080.US	Owned by Zseventy	US	16/348450	US 2019/0350974 A1	TGF BETA SIGNAL CONVERTOR	11/17/2016	11/17/2017	05/23/2023	GRANTED	11/16/2037
BLUE-080.ZA	Owned by Zseventy	ZA	2019/03076		TGF BETA SIGNAL CONVERTOR	11/17/2016	05/16/2019		PENDING	
Zseventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-092AU	Owned by Zseventy	AU	2018385699	2018385699	DARIC INTERLEUKIN RECEPTORS	12/14/2017	06/18/2020		PUBLISHED	
BLUE-092D1	Owned by Zseventy	US	18/595641		DARIC INTERLEUKIN RECEPTORS	12/14/2017	03/05/2024		PENDING	
BLUE-092CA	Owned by Zseventy	CA	3084551	3084551	DARIC INTERLEUKIN RECEPTORS	12/14/2017	06/02/2020		PUBLISHED	
BLUE-092CN	Owned by Zseventy	CN	201880086118.7	111565737	DARIC INTERLEUKIN RECEPTORS	12/14/2017	07/10/2020		PUBLISHED	

BLUE-092EP	Owned by Zseventy	EP	18888801.0	3723787	DARIC INTERLEUKIN RECEPTORS	12/14/2017	06/11/2020		PUBLISHED	
BLUE-092HK	Owned by Zseventy	HK	62021028403.5	40038635	DARIC INTERLEUKIN RECEPTORS	12/14/2017	03/29/2021		PUBLISHED	
BLUE-092IL	Owned by Zseventy	IL	275079	275079	DARIC INTERLEUKIN RECEPTORS	12/14/2017	06/02/2020		PUBLISHED	
BLUE-092JP	Owned by Zseventy	JP	2020-532804	2021-506271	DARIC INTERLEUKIN RECEPTORS	12/14/2017	06/12/2020		PUBLISHED	
BLUE-092KR	Owned by Zseventy	KR	10-2020-7020228	10-2020-0110326	DARIC INTERLEUKIN RECEPTORS	12/14/2017	07/13/2020		PUBLISHED	
BLUE-092P1	Owned by Zseventy	US	62/598923		DARIC INTERLEUKIN RECEPTORS	12/14/2017	12/14/2017		CONV COMPLE	12/14/2018
BLUE-092PC	Owned by Zseventy	WO	PCT/US2018/065786	WO 2019/118895	DARIC INTERLEUKIN RECEPTORS	12/14/2017	12/14/2018		COMPLETED	
BLUE-092USPC	Owned by Zseventy	US	16/771402	US-2020-0392204-A1	DARIC INTERLEUKIN RECEPTORS	12/14/2017	06/10/2020		ALLOWED	
Zseventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-098EP	Owned by Zseventy	EP	19784626.4	3781188	ADOPTIVE CELLULAR THERAPY	04/13/2018	10/21/2020		ABANDONED	
BLUE-098P1	Owned by Zseventy	US	62/657388		ADOPTIVE CELLULAR THERAPY	04/13/2018	04/13/2018		CONV COMPLE	04/13/2019
BLUE-098PC	Owned by Zseventy	WO	PCT/US2019/027317	WO 2019/200316	ADOPTIVE CELLULAR THERAPY	04/13/2018	04/12/2019		COMPLETED	
BLUE-098USPC	Owned by Zseventy	US	17/046466	US-2021-0252084-A1	ADOPTIVE CELLULAR THERAPY	04/13/2018	10/09/2020		ALLOWED	
Zseventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-101.NZ	Owned by Zseventy	NZ	771249	771249	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	12/17/2020		PUBLISHED	
BLUE-101AU	Owned by Zseventy	AU	2019287720	2019287720	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	12/17/2020		PUBLISHED	
BLUE-101BR	Owned by Zseventy	BR	BR112020025439-8	BR112020025439-8	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	12/22/2020		PUBLISHED	
BLUE-101CA	Owned by Zseventy	CA	3110836	3110836	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	12/07/2020		PUBLISHED	
BLUE-101CN	Owned by Zseventy	CN	201980045873.5	112368021	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	01/07/2021		PUBLISHED	
BLUE-101EP	Owned by Zseventy	EP	19819809.5	3806903	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	12/10/2020		PUBLISHED	
BLUE-101EP2	Owned by Zseventy	EP	24150405.90		CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	01/04/2024		FILED	
BLUE-101HK	Owned by Zseventy	HK	62021040649.7	40052400	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	10/18/2021		PUBLISHED	
BLUE-101IL	Owned by Zseventy	IL	279310	279310	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	12/09/2020		PUBLISHED	
BLUE-101JP	Owned by Zseventy	JP	2020-569179	2021-527409	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	12/11/2020		PUBLISHED	
BLUE-101KR	Owned by Zseventy	KR	10-2021-7000376	10-2021-7000376	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	01/06/2021		PUBLISHED	
BLUE-101P1	Owned by Zseventy	US	62/685078		CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	06/14/2018		CONV COMPLE	06/14/2019
BLUE-101PC	Owned by Zseventy	WO	PCT/US2019/037270	WO 2019/241685	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	06/14/2019		COMPLETED	
BLUE-101SG	Owned by Zseventy	SG	11202012155R	11202012155R	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	12/07/2020		PUBLISHED	
BLUE-101USPC	Owned by Zseventy	US	16/973879	US-2021-0261659-A1	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	12/10/2020		PUBLISHED	
Zseventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-103.HK	Owned by Zseventy	HK	62022054426.1	40065363A	METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS	01/22/2019	06/01/2022		PUBLISHED	01/22/2040
BLUE-103AU	Owned by Zseventy	AU	2020211990	2020211990	METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS	01/23/2019	07/22/2021		ABANDONED	
BLUE-103CN	Owned by Zseventy	CN	202080016565.2	114206103	METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS	01/24/2019	01/22/2020		ABANDONED	
BLUE-103EP	Owned by Zseventy	EP	20744882.0	3914067	METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS	01/25/2019	08/20/2021		ABANDONED	
BLUE-103JP	Owned by Zseventy	JP	2021-543160	2022-523044	METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS	01/26/2019	07/26/2021		ABANDONED	
BLUE-103P1	Owned by Zseventy	US	62/795513		METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS	01/27/2019	01/23/2019		CONV COMPLE	01/22/2020
BLUE-103PC	Owned by Zseventy	WO	PCT/US2020/014668	WO 2020/154445	METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS	01/28/2019	01/22/2020		COMPLETED	
BLUE-103USPC	Owned by Zseventy	US	17/425309	US-2022-0106610-A1	METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS	01/29/2019	07/22/2021		PUBLISHED	
Zseventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-111P1	Owned by Zseventy	US	62/779882		DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	12/14/2018		CONV COMPLE	12/14/2019
BLUE-111PC	Owned by Zseventy	WO	PCT/US2019/066216	WO 2020/123933	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	12/13/2019		COMPLETED	
BLUE-111USPC	Owned by Zseventy	US	17/311767		DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	06/08/2021		PENDING	
Zseventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-112.HK	Owned by Zseventy	HK	62022051920.6	40063501 A	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	04/19/2022		PUBLISHED	12/13/2039
BLUE-112AU	Owned by Zseventy	AU	2019397152	2019397152	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	06/09/2021		ABANDONED	
BLUE-112CA	Owned by Zseventy	CA	3121942	3121942	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	06/02/2021		ABANDONED	
BLUE-112CN	Owned by Zseventy	CN	201980090408.3	113412276	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	07/27/2021		ABANDONED	
BLUE-112EP	Owned by Zseventy	EP	19896079.1	3894436	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	07/08/2021		ABANDONED	
BLUE-112JP	Owned by Zseventy	JP	2021-533529	2022-512475	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	06/11/2021		ABANDONED	
BLUE-112P1	Owned by Zseventy	US	62/779889		DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	12/14/2018		CONV COMPLE	12/14/2019
BLUE-112P2	Owned by Zseventy	US	62/835658		DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	04/18/2019	04/18/2019		CONV COMPLE	04/18/2020
BLUE-112PC	Owned by Zseventy	WO	PCT/US2019/066219	WO 2020/123936	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	12/13/2019		COMPLETED	
BLUE-112USPC	Owned by Zseventy	US	17/311776		DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	06/08/2021		PENDING	
Zseventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-113.HK	Owned by Zseventy	HK	62022051923.0	40063502	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	04/19/2022		PUBLISHED	12/13/2039
BLUE-113AU	Owned by Zseventy	AU	2019396553	2019396553	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	06/09/2021		PUBLISHED	
BLUE-113CA	Owned by Zseventy	CA	3123084	3123084	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	06/11/2021		PUBLISHED	
BLUE-113CN	Owned by Zseventy	CN	201980091143.9	113366479	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	08/03/2021		PUBLISHED	
BLUE-113EP	Owned by Zseventy	EP	19896568.3	3895052	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	07/08/2021		PUBLISHED	
BLUE-113IL	Owned by Zseventy	IL	283897	283897	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	06/10/2021		PUBLISHED	
BLUE-113JP	Owned by Zseventy	JP	2021-533530	2022-513460	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	06/11/2021		PUBLISHED	
BLUE-113KR	Owned by Zseventy	KR	10-2021-7021631	10-2021-0104772	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	07/09/2021		PUBLISHED	
BLUE-113P1	Owned by Zseventy	US	62/779971		DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	12/14/2018		CONV COMPLE	
BLUE-113P2	Owned by Zseventy	US	62/835659		DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	04/18/2019	04/08/2019		CONV COMPLE	04/08/2020
BLUE-113PC	Owned by Zseventy	WO	PCT/US2019/066223	WO 2020/123938	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	12/13/2019		COMPLETED	
BLUE-113USPC	Owned by Zseventy	US	17/312120	US-2022-0031750-A1	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	06/09/2021		PUBLISHED	
Zseventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-114P1	Owned by Zseventy	US	62/779953		DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	12/14/2018		CONV COMPLE	12/14/2019
BLUE-114P2	Owned by Zseventy	US	62/835662		DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	04/18/2019	04/18/2019		CONV COMPLE	04/18/2020
BLUE-114PC	Owned by Zseventy	WO	PCT/US2019/066241	WO 2020/123947	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	12/13/2019		COMPLETED	
BLUE-114USPC	Owned by Zseventy	US	17/312116	US-2022-0025014-A1	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	06/09/2021		PUBLISHED	
Zseventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-115.AU	Co-Owned Medigene/Zseventy	AU	2020249598.00		MAGE A4 T CELL RECEPTORS	03/27/2019	03/27/2020		PENDING	
BLUE-115.BR	Co-Owned Medigene/Zseventy	BR	BR112021019066-0	BR112021019066-0 A2	MAGE A4 T CELL RECEPTORS	03/27/2019	03/27/2020		PUBLISHED	
BLUE-115.CA	Co-Owned Medigene/Zseventy	CA	3134076.00	3134076	MAGE A4 T CELL RECEPTORS	03/27/2019	03/27/2020		PUBLISHED	
BLUE-115.CL	Co-Owned Medigene/Zseventy	CL	202102491.00		MAGE A4 T CELL RECEPTORS	03/27/2019	03/27/2020		PUBLISHED	
BLUE-115.CN	Co-Owned Medigene/Zseventy	CN	202080039452.40	CN 114126716 A	MAGE A4 T CELL RECEPTORS	03/27/2019	03/27/2020		PUBLISHED	
BLUE-115.CO	Co-Owned Medigene/Zseventy	CO	NC2021/0012587	2021/0012587	MAGE A4 T CELL RECEPTORS	03/27/2019	03/27/2020		PUBLISHED	
BLUE-115.EA	Co-Owned Medigene/Zseventy	EA	202192327.00	202192327	MAGE A4 T CELL RECEPTORS	03/27/2019	03/27/2020		PUBLISHED	

BLUE-115.EP2	Co-Owned Medigene/2seventy	EP	20719942.30	3946621	MAGE A4 T CELL RECEPTORS	03/27/2019	03/27/2020		PUBLISHED	
BLUE-115.HK2	Co-Owned Medigene/2seventy	HK	62022056770.00	HK40067706	MAGE A4 T CELL RECEPTORS	03/27/2019	10/27/2021		PUBLISHED	
BLUE-115.ID	Co-Owned Medigene/2seventy	ID	P00202107870		MAGE A4 T CELL RECEPTORS	03/27/2019	03/27/2020		PENDING	
BLUE-115.IL	Co-Owned Medigene/2seventy	IL	286569.00		MAGE A4 T CELL RECEPTORS	03/27/2019	03/27/2020		PENDING	
BLUE-115.IN	Co-Owned Medigene/2seventy	IN	202117043416.00		MAGE A4 T CELL RECEPTORS	03/27/2019	03/27/2020		PENDING	
BLUE-115.JP	Co-Owned Medigene/2seventy	JP	2021-560302	2022-527635	MAGE A4 T CELL RECEPTORS	03/27/2019	03/27/2020		PUBLISHED	
BLUE-115.KR	Co-Owned Medigene/2seventy	KR	10-2021-7035022	10-2021-0150440 A	MAGE A4 T CELL RECEPTORS	03/27/2019	03/27/2020		PUBLISHED	
BLUE-115.MX	Co-Owned Medigene/2seventy	MX	MX/a/2021/011613		MAGE A4 T CELL RECEPTORS	03/27/2019	03/27/2020		PENDING	
BLUE-115.PC	Co-Owned Medigene/2seventy	PCT	PCT/EP20/58779	WO 2020/193767 A1	MAGE A4 T CELL RECEPTORS	03/27/2019	03/27/2020		EXPIRED	
BLUE-115.SG	Co-Owned Medigene/2seventy	SG	11202110171Q		MAGE A4 T CELL RECEPTORS	03/27/2019	03/27/2020		PENDING	
BLUE-115.USPC	Co-Owned Medigene/2seventy	US	17/441861	US 2023/0159612 A1	MAGE A4 T CELL RECEPTORS	03/27/2019	09/22/2021		PUBLISHED	
Zseventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-119AU	Co-Owned Inhibrx/2seventy	AU	2020268379	2020268379	CD33 TARGETED IMMUNOTHERAPIES	05/08/2019	12/06/2021		PUBLISHED	
BLUE-119BR	Co-Owned Inhibrx/2seventy	BR	BR112021022356-8	BR112021022356-8	CD33 TARGETED IMMUNOTHERAPIES	05/08/2019	05/07/2020		PUBLISHED	
BLUE-119CA	Co-Owned Inhibrx/2seventy	CA	3139096	3139096	CD33 TARGETED IMMUNOTHERAPIES	05/08/2019	11/03/2021		PUBLISHED	
BLUE-119CN	Co-Owned Inhibrx/2seventy	CN	202080048661.5	114206928	CD33 TARGETED IMMUNOTHERAPIES	05/08/2019	05/07/2020		PUBLISHED	05/07/2040
BLUE-119EA	Co-Owned Inhibrx/2seventy	EA	202193072	202193072	CD33 TARGETED IMMUNOTHERAPIES	05/08/2019	12/08/2021		ALLOWED	05/07/2040
BLUE-119EP	Co-Owned Inhibrx/2seventy	EP	20802310.1	3966251	CD33 TARGETED IMMUNOTHERAPIES	05/08/2019	12/08/2021		PUBLISHED	
BLUE-119HK	Co-Owned Inhibrx/2seventy	HK	62022059634.5	40071127 A	CD33 TARGETED IMMUNOTHERAPIES	05/08/2019	09/06/2022		PUBLISHED	
BLUE-119ID	Co-Owned Inhibrx/2seventy	ID	P00202109620	2022/01551	CD33 TARGETED IMMUNOTHERAPIES	05/08/2019	05/07/2020		PUBLISHED	05/07/2040
BLUE-119IL	Co-Owned Inhibrx/2seventy	IL	287770	287770	CD33 TARGETED IMMUNOTHERAPIES	05/08/2019	11/01/2021		PUBLISHED	
BLUE-119IN	Co-Owned Inhibrx/2seventy	IN	202117052238		CD33 TARGETED IMMUNOTHERAPIES	05/08/2019	05/07/2020		PUBLISHED	
BLUE-119JP	Co-Owned Inhibrx/2seventy	JP	2021-566152	2022-531719	CD33 TARGETED IMMUNOTHERAPIES	05/08/2019	05/07/2020		PUBLISHED	
BLUE-119KR	Co-Owned Inhibrx/2seventy	KR	10-2021-7040150	10-2022-0031554	CD33 TARGETED IMMUNOTHERAPIES	05/08/2019	12/07/2021		PUBLISHED	
BLUE-119MX	Co-Owned Inhibrx/2seventy	MX	MX/a/2021/013591		CD33 TARGETED IMMUNOTHERAPIES	05/08/2019	11/05/2021		PENDING	
BLUE-119P1	Co-Owned Inhibrx/2seventy	US	62/845304		CD33 TARGETED IMMUNOTHERAPIES	05/08/2019	05/08/2019		CONV COMPLE	05/08/2020
BLUE-119P2	Co-Owned Inhibrx/2seventy	US	62/898392		CD33 TARGETED IMMUNOTHERAPIES	09/10/2019	09/10/2019		CONV COMPLE	09/10/2020
BLUE-119PC	Co-Owned Inhibrx/2seventy	WO	PCT/US2020/031780	WO 2020/227474	CD33 TARGETED IMMUNOTHERAPIES	05/08/2019	05/07/2020		COMPLETED	
BLUE-119SG	Co-Owned Inhibrx/2seventy	SG	11202111890R	11202111890R	CD33 TARGETED IMMUNOTHERAPIES	05/08/2019	10/26/2021		ABANDONED	
BLUE-119SG2	Co-Owned Inhibrx/2seventy	SG	10202204765Y		CD33 TARGETED IMMUNOTHERAPIES	05/08/2019	05/06/2022		PENDING	05/07/2040
BLUE-119USPC	Co-Owned Inhibrx/2seventy	US	17/608743	US-2022-0324942-A1	CD33 TARGETED IMMUNOTHERAPIES	05/08/2019	11/03/2021		PUBLISHED	
Zseventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-120AU	Co-Owned Inhibrx/2seventy	AU	2020267639	2020267639	CLL-1 TARGETED IMMUNOTHERAPIES	05/08/2019	12/06/2021		PUBLISHED	
BLUE-120BR	Co-Owned Inhibrx/2seventy	BR	BR112021022365-7	BR112021022365-7	CLL-1 TARGETED IMMUNOTHERAPIES	05/08/2019	05/07/2020		PUBLISHED	
BLUE-120CA	Co-Owned Inhibrx/2seventy	CA	3148027	3148027	CLL-1 TARGETED IMMUNOTHERAPIES	05/08/2019	11/02/2021		PUBLISHED	
BLUE-120CN	Co-Owned Inhibrx/2seventy	CN	202080049880.5	114502586A	CLL-1 TARGETED IMMUNOTHERAPIES	05/08/2019	05/07/2020		PUBLISHED	05/07/2040
BLUE-120EA	Co-Owned Inhibrx/2seventy	EA	202193071		CLL-1 TARGETED IMMUNOTHERAPIES	05/08/2019	12/08/2021		PENDING	
BLUE-120EP	Co-Owned Inhibrx/2seventy	EP	20801987.7	3966249	CLL-1 TARGETED IMMUNOTHERAPIES	05/08/2019	12/06/2021		PUBLISHED	
BLUE-120HK	Co-Owned Inhibrx/2seventy	HK	62022059633.7	40071126	CLL-1 TARGETED IMMUNOTHERAPIES	05/08/2019	09/06/2022		PUBLISHED	
BLUE-120ID	Co-Owned Inhibrx/2seventy	ID	P00202109626	2022/01934	CLL-1 TARGETED IMMUNOTHERAPIES	05/08/2019	05/07/2020		PUBLISHED	
BLUE-120ID2	Co-Owned Inhibrx/2seventy	ID			CLL-1 TARGETED IMMUNOTHERAPIES	05/08/2019			UNFILED	
BLUE-120IL	Co-Owned Inhibrx/2seventy	IL	287769	287769	CLL-1 TARGETED IMMUNOTHERAPIES	05/08/2019	11/01/2021		PUBLISHED	
BLUE-120IN	Co-Owned Inhibrx/2seventy	IN	202117052262		CLL-1 TARGETED IMMUNOTHERAPIES	05/08/2019	05/07/2020		PUBLISHED	
BLUE-120JP	Co-Owned Inhibrx/2seventy	JP	2021-566149	2022-532556	CLL-1 TARGETED IMMUNOTHERAPIES	05/08/2019	05/07/2020		PUBLISHED	
BLUE-120KR	Co-Owned Inhibrx/2seventy	KR	10-2021-7039632	10-2022-0031549	CLL-1 TARGETED IMMUNOTHERAPIES	05/08/2019	12/02/2021		PUBLISHED	
BLUE-120MX	Co-Owned Inhibrx/2seventy	MX	MX/a/2021/013590		CLL-1 TARGETED IMMUNOTHERAPIES	05/08/2019	11/05/2021		PENDING	
BLUE-120P1	Co-Owned Inhibrx/2seventy	US	62/845306		CLL-1 TARGETED IMMUNOTHERAPIES	05/08/2019	05/08/2019		CONV COMPLE	05/08/2020
BLUE-120PC	Co-Owned Inhibrx/2seventy	WO	PCT/US2020/031781	WO 2020/227475	CLL-1 TARGETED IMMUNOTHERAPIES	05/08/2019	05/07/2020		COMPLETED	
BLUE-120SG	Co-Owned Inhibrx/2seventy	SG	11202111927Q	11202111927Q	CLL-1 TARGETED IMMUNOTHERAPIES	05/08/2019	10/27/2021		ABANDONED	
BLUE-120SG2	Co-Owned Inhibrx/2seventy	SG	10202204769R		CLL-1 TARGETED IMMUNOTHERAPIES	05/08/2019	05/06/2022		PENDING	05/07/2040
BLUE-120USPC	Co-Owned Inhibrx/2seventy	US	17/608738	US-2022-0323496-A1	CLL-1 TARGETED IMMUNOTHERAPIES	05/08/2019	11/03/2021		PUBLISHED	
Zseventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-122AU	Co-Owned Medigene/2seventy	AU	2020267641.00	2020267641	ENGINEERED T CELLS	05/08/2019	05/07/2020		PUBLISHED	
BLUE-122BR	Co-Owned Medigene/2seventy	BR	BR112021022303-7		ENGINEERED T CELLS	05/08/2019	05/07/2020		PUBLISHED	
BLUE-122CA	Co-Owned Medigene/2seventy	CA	3139011.00	3139011	ENGINEERED T CELLS	05/08/2019	05/07/2020		PUBLISHED	
BLUE-122.CL	Co-Owned Medigene/2seventy	CL	202102935.00	2167069	ENGINEERED T CELLS	05/08/2019	05/07/2020		PUBLISHED	
BLUE-122.CN	Co-Owned Medigene/2seventy	CN	202080044323.40	CN114375301A	ENGINEERED T CELLS	05/08/2019	05/07/2020		PUBLISHED	
BLUE-122.CO	Co-Owned Medigene/2seventy	CO	NC2021/0016480	NC2021/0016480	ENGINEERED T CELLS	05/08/2019	05/07/2020		PUBLISHED	
BLUE-122.EA	Co-Owned Medigene/2seventy	EA	202193074.00	202193074	ENGINEERED T CELLS	05/08/2019	05/07/2020		PUBLISHED	
BLUE-122.EP	Co-Owned Medigene/2seventy	EP	20802730.00	3966235	ENGINEERED T CELLS	05/08/2019	05/07/2020		PUBLISHED	
BLUE-122.HK	Co-Owned Medigene/2seventy	HK	62022060245.70	HK40070747	ENGINEERED T CELLS	05/08/2019	05/07/2020		PUBLISHED	
BLUE-122.ID	Co-Owned Medigene/2seventy	ID	P00202109643	2023/02860	ENGINEERED T CELLS	05/08/2019	05/07/2020		PUBLISHED	
BLUE-122.IL	Co-Owned Medigene/2seventy	IL	287777.00		ENGINEERED T CELLS	05/08/2019	05/07/2020		PENDING	
BLUE-122.IN	Co-Owned Medigene/2seventy	IN	202117052411.00	202117052411 A	ENGINEERED T CELLS	05/08/2019	05/07/2020		PUBLISHED	
BLUE-122.JP	Co-Owned Medigene/2seventy	JP	2021-566150	2022-532557	ENGINEERED T CELLS	05/08/2019	05/07/2020		PUBLISHED	
BLUE-122.KR	Co-Owned Medigene/2seventy	KR	10-2021-7039633	10-2022-0030933	ENGINEERED T CELLS	05/08/2019	05/07/2020		PUBLISHED	
BLUE-122.MX	Co-Owned Medigene/2seventy	MX	MX/a/2021/013588		ENGINEERED T CELLS	05/08/2019	05/07/2020		PENDING	
BLUE-122.P1	Co-Owned Medigene/2seventy	US	62/845311		ENGINEERED T CELLS	05/08/2019	05/08/2019		EXPIRED	
BLUE-122.PC	Co-Owned Medigene/2seventy	PCT	PCT/US20/31796	WO 2020/227483 A1	ENGINEERED T CELLS	05/08/2019	05/07/2020		Nationalize	
BLUE-122.SG	Co-Owned Medigene/2seventy	SG	11202111973R		ENGINEERED T CELLS	05/08/2019	05/07/2020		ABANDONED	
BLUE-122.SG	Co-Owned Medigene/2seventy	SG	10202204766X		ENGINEERED T CELLS	05/08/2019	05/07/2020		PUBLISHED	
BLUE-122.USPC	Co-Owned Medigene/2seventy	US	17/608860	2023-0044580	ENGINEERED T CELLS	05/08/2019	11/04/2021		PUBLISHED	
Zseventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-123AU	Owned by Zseventy	AU	2020291922	2020291922	COMPOSITIONS AND METHODS FOR TREATING CANCER	06/14/2019	01/12/2022		PUBLISHED	
BLUE-123BR	Owned by Zseventy	BR	BR112021025259-2		COMPOSITIONS AND METHODS FOR TREATING CANCER	06/14/2019	06/11/2020		PENDING	
BLUE-123CA	Owned by Zseventy	CA	3143248	3143248	COMPOSITIONS AND METHODS FOR TREATING CANCER	06/14/2019	12/10/2021		PUBLISHED	
BLUE-123CN	Owned by Zseventy	CN	202080052834.0	CN114206936	COMPOSITIONS AND METHODS FOR TREATING CANCER	06/14/2019	01/21/2022		PUBLISHED	06/11/2040
BLUE-123EA	Owned by Zseventy	EA	202290071	202290071	COMPOSITIONS AND METHODS FOR TREATING CANCER	06/14/2019	06/11/2020		PUBLISHED	
BLUE-123EP	Owned by Zseventy	EP	20821693.7	3983445	COMPOSITIONS AND METHODS FOR TREATING CANCER	06/14/2019	12/09/2021		PUBLISHED	
BLUE-123HK	Owned by Zseventy	HK	62022061576.4	40072464A	COMPOSITIONS AND METHODS FOR TREATING CANCER	06/14/2019	09/30/2022		PUBLISHED	06/11/2040
BLUE-123ID	Owned by Zseventy	ID	P00202200270	2023/04181	COMPOSITIONS AND METHODS FOR TREATING CANCER	06/14/2019	06/11/2020		PUBLISHED	06/11/2040
BLUE-123IL	Owned by Zseventy	IL	288914		COMPOSITIONS AND METHODS FOR TREATING CANCER	06/14/2019	12/12/2021		PENDING	
BLUE-123IN	Owned by Zseventy	IN	202217000553	202217000553	COMPOSITIONS AND METHODS FOR TREATING CANCER	06/14/2019	06/11/2020		PUBLISHED	

BLUE-123JP	Owned by Zseventy	JP	2021-573844	2022-537159	COMPOSITIONS AND METHODS FOR TREATING CANCER	06/14/2019	06/11/2020		PUBLISHED	
BLUE-123KR	Owned by Zseventy	KR	10-2022-7001320	10-2022-0033485	COMPOSITIONS AND METHODS FOR TREATING CANCER	06/14/2019	01/13/2022		PUBLISHED	
BLUE-123MX	Owned by Zseventy	MX	MX/A/2021/015495		COMPOSITIONS AND METHODS FOR TREATING CANCER	06/14/2019	06/11/2020		PUBLISHED	
BLUE-123NZ	Owned by Zseventy	NZ	784226	784226	COMPOSITIONS AND METHODS FOR TREATING CANCER	06/14/2019	01/12/2022		PUBLISHED	
BLUE-123P1	Owned by Zseventy	US	62/861838		COMPOSITIONS AND METHODS FOR TREATING CANCER	06/14/2019	06/14/2019		CONV COMPLE	06/14/2020
BLUE-123P2	Owned by Zseventy	US	62/991314		COMPOSITIONS AND METHODS FOR TREATING CANCER	03/08/2020	03/18/2020		CONV COMPLE	03/18/2021
BLUE-123PC	Owned by Zseventy	WO	PCT/US2020/037145	WO 2020/252110	COMPOSITIONS AND METHODS FOR TREATING CANCER	06/14/2019	06/11/2020		COMPLETED	
BLUE-123SG	Owned by Zseventy	SG	11202113613V		COMPOSITIONS AND METHODS FOR TREATING CANCER	06/14/2019	12/08/2021		ABANDONED	
BLUE-123SG2	Owned by Zseventy	SG	10202250134K		COMPOSITIONS AND METHODS FOR TREATING CANCER	06/14/2019	06/13/2022			06/11/2040
BLUE-123USPC	Owned by Zseventy	US	17/618747	US-2022-0280567-A1	COMPOSITIONS AND METHODS FOR TREATING CANCER	06/14/2019	12/13/2021		PUBLISHED	
Zseventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-125P1	Owned by Zseventy	US	62/925800		CELL CULTURE MEDIUM	10/25/2019	10/25/2019		CONV COMPLE	10/25/2020
BLUE-125US	Owned by Zseventy	US	17/077134		CELL CULTURE MEDIUM	10/25/2019	10/22/2020		ALLOWED	
Zseventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-127AU	Owned by Zseventy	AU	2021255702		MODIFIED CCR POLYPEPTIDES AND USES THEREOF	04/17/2020	10/19/2022		PENDING	04/16/2041
BLUE-127CA	Owned by Zseventy	CA	3180329	3180329	MODIFIED CCR POLYPEPTIDES AND USES THEREOF	04/17/2020	10/14/2022		PUBLISHED	04/16/2041
BLUE-127CN	Owned by Zseventy	CN	202180028320.8	115397864	MODIFIED CCR POLYPEPTIDES AND USES THEREOF	04/17/2020	10/13/2022		PUBLISHED	04/16/2041
BLUE-127EP	Owned by Zseventy	EP	21789050.8	4136119	MODIFIED CCR POLYPEPTIDES AND USES THEREOF	04/17/2020	11/04/2022		PUBLISHED	04/16/2041
BLUE-127HK	Owned by Zseventy	HK	62023075915.6	40087431A	MODIFIED CCR POLYPEPTIDES AND USES THEREOF	04/17/2020	07/12/2023		PUBLISHED	
BLUE-127JP	Owned by Zseventy	JP	2022-562711	2023-522038	MODIFIED CCR POLYPEPTIDES AND USES THEREOF	04/17/2020	10/14/2022		PUBLISHED	04/16/2041
BLUE-127KR	Owned by Zseventy	KR	10-2022-7035279	10-2023-0005147	MODIFIED CCR POLYPEPTIDES AND USES THEREOF	04/17/2020	10/11/2022		PUBLISHED	04/16/2041
BLUE-127P1	Owned by Zseventy	US	63/011494		MODIFIED CCR POLYPEPTIDES AND USES THEREOF	04/17/2020	04/17/2020		CONV COMPLE	04/17/2021
BLUE-127PC	Owned by Zseventy	WO	PCT/US2021/027648	WO 2021/211948	MODIFIED CCR POLYPEPTIDES AND USES THEREOF	04/17/2020	04/16/2021		COMPLETED	
BLUE-127USPC	Owned by Zseventy	US	17/918830		MODIFIED CCR POLYPEPTIDES AND USES THEREOF	04/17/2020	10/13/2022		PENDING	
Zseventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-128AU	Owned by Zseventy	AU	2021286651		METHODS FOR MANUFACTURING VIRAL VECTORS	06/11/2020	11/28/2022		PENDING	06/10/2041
BLUE-128CA	Owned by Zseventy	CA	3194520		METHODS FOR MANUFACTURING VIRAL VECTORS	06/11/2020	11/30/2022		PENDING	06/10/2041
BLUE-128CN	Owned by Zseventy	CN	202180038239.6	115698305	METHODS FOR MANUFACTURING VIRAL VECTORS	06/11/2020	11/25/2022		PUBLISHED	06/10/2041
BLUE-128EP	Owned by Zseventy	EP	21821063.1	4165197	METHODS FOR MANUFACTURING VIRAL VECTORS	06/11/2020	11/28/2022		PUBLISHED	06/10/2041
BLUE-128HK	Owned by Zseventy	HK	62023079449.2	40091254	METHODS FOR MANUFACTURING VIRAL VECTORS	06/11/2020	09/20/2023		PUBLISHED	
BLUE-128JP	Owned by Zseventy	JP	2022-572331	2023-528776	METHODS FOR MANUFACTURING VIRAL VECTORS	06/11/2020	11/24/2022		PUBLISHED	06/10/2041
BLUE-128KR	Owned by Zseventy	KR	10-2022-7040912	10-2023-0024891	METHODS FOR MANUFACTURING VIRAL VECTORS	06/11/2020	11/22/2022		PUBLISHED	06/10/2041
BLUE-128P1	Owned by Zseventy	US	63/037777		METHODS FOR MANUFACTURING VIRAL VECTORS	06/11/2020	06/11/2020		CONV COMPLE	06/11/2021
BLUE-128PC	Owned by Zseventy	WO	PCT/US2021/036840	WO 2021/252782	METHODS FOR MANUFACTURING VIRAL VECTORS	06/11/2020	06/10/2021		COMPLETED	
BLUE-128SG	Owned by Zseventy	SG	11202260385U		METHODS FOR MANUFACTURING VIRAL VECTORS	06/11/2020	11/18/2022		Await CADs	06/10/2041
BLUE-128SG2	Owned by Zseventy	SG	10202301481Q		METHODS FOR MANUFACTURING VIRAL VECTORS	06/11/2020	05/25/2023		PENDING	06/10/2041
BLUE-128USPC	Owned by Zseventy	US	18/009239	US-2023-0212591-A1	METHODS FOR MANUFACTURING VIRAL VECTORS	06/11/2020	12/08/2022		PUBLISHED	
Zseventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-129P1	Owned by Zseventy	US	63/007990		FRB ANTIBODIES	04/10/2020	04/10/2020		COMPLETED	04/10/2021
BLUE-129PC	Owned by Zseventy	WO	PCT/US2021/026597	WO 2021/207613	FRB ANTIBODIES	04/10/2020	04/09/2021		PUBLISHED	
BLUE-129USPC	Owned by Zseventy	US	17/917418	US-2023-0151117-A1	FRB ANTIBODIES	04/10/2020	10/06/2022		PUBLISHED	
Zseventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-130AU	Owned by Zseventy	AU	2021244594		T CELL RECEPTORS	03/27/2020	10/26/2022		PENDING	03/26/2041
BLUE-130BR	Owned by Zseventy	BR	BR112022019380-7		T CELL RECEPTORS	03/27/2020	09/26/2022		PENDING	
BLUE-130CA	Owned by Zseventy	CA	3177181	3177181	T CELL RECEPTORS	03/27/2020	09/26/2022		PUBLISHED	03/26/2041
BLUE-130CN	Owned by Zseventy	CN	202180032592.3	115485294	T CELL RECEPTORS	03/27/2020	11/02/2022		PUBLISHED	03/26/2041
BLUE-130EA	Owned by Zseventy	EA	202292764		T CELL RECEPTORS	03/27/2020	10/27/2022		PENDING	03/26/2041
BLUE-130EP	Owned by Zseventy	EP	21775262.5	4126924	T CELL RECEPTORS	03/27/2020	10/21/2022		PUBLISHED	03/26/2041
BLUE-130HK	Owned by Zseventy	HK	62023073058.7	HK40083795	T CELL RECEPTORS	03/27/2020	05/17/2023		PUBLISHED	03/26/2041
BLUE-130IL	Owned by Zseventy	IL	296827		T CELL RECEPTORS	03/27/2020	09/28/2022		PENDING	03/26/2041
BLUE-130JP	Owned by Zseventy	JP	2022-558271	2023-519868	T CELL RECEPTORS	03/27/2020	09/26/2022		PUBLISHED	03/26/2041
BLUE-130KR	Owned by Zseventy	KR	10-2022-7036819	10-2022-0160040	T CELL RECEPTORS	03/27/2020	10/21/2022		PUBLISHED	03/26/2041
BLUE-130MX	Owned by Zseventy	MX	MX/A/2022/012062	MX/A/2022/012062	T CELL RECEPTORS	03/27/2020	09/27/2022		PUBLISHED	03/26/2041
BLUE-130NZ	Owned by Zseventy	NZ	793783		T CELL RECEPTORS	03/27/2020	10/26/2022		PENDING	03/26/2041
BLUE-130P1	Owned by Zseventy	US	63/000800		T CELL RECEPTORS	03/27/2020	03/27/2020		CONV COMPLE	03/27/2021
BLUE-130PC	Owned by Zseventy	WO	PCT/US2021/024370	WO 2021/195503	T CELL RECEPTORS	03/27/2020	03/26/2021		PUBLISHED	
BLUE-130SG	Owned by Zseventy	SG	11202253538K		T CELL RECEPTORS	03/27/2020	09/27/2022		Await CADs	
BLUE-130SG2	Owned by Zseventy	SG	10202300761R		T CELL RECEPTORS	03/27/2020	03/21/2023		PENDING	03/26/2041
BLUE-130USPC	Owned by Zseventy	US	17/914483	US-2023-0124640-A1	T CELL RECEPTORS	03/27/2020	09/26/2022		PUBLISHED	
Zseventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-131AU	Owned by Zseventy	AU	2021330958		BCMA CHIMERIC ANTIGEN RECEPTORS	08/25/2020	03/17/2023		PENDING	08/24/2041
BLUE-131BR	Owned by Zseventy	BR	BR112023003337-3		BCMA CHIMERIC ANTIGEN RECEPTORS	08/25/2020	02/23/2023		PENDING	
BLUE-131CA	Owned by Zseventy	CA	3191855	3191855	BCMA CHIMERIC ANTIGEN RECEPTORS	08/25/2020	02/14/2023		PUBLISHED	08/24/2041
BLUE-131CN	Owned by Zseventy	CN	202180070491.5	116348496	BCMA CHIMERIC ANTIGEN RECEPTORS	08/25/2020	04/14/2023		PUBLISHED	08/24/2041
BLUE-131EP	Owned by Zseventy	EP	21862543.2	4204457	BCMA CHIMERIC ANTIGEN RECEPTORS	08/25/2020	03/02/2023		PUBLISHED	08/24/2041
BLUE-131HK	Owned by Zseventy	HK	62023084024.6		BCMA CHIMERIC ANTIGEN RECEPTORS	08/25/2020	12/12/2023		PENDING	08/24/2041
BLUE-131IL	Owned by Zseventy	IL	300612		BCMA CHIMERIC ANTIGEN RECEPTORS	08/25/2020	02/13/2023		PENDING	08/24/2041
BLUE-131JP	Owned by Zseventy	JP	2023-513346	2023-539591	BCMA CHIMERIC ANTIGEN RECEPTORS	08/25/2020	02/24/2023		PUBLISHED	08/24/2041
BLUE-131KR	Owned by Zseventy	KR	10-2023-7009062	10-2023-0053650	BCMA CHIMERIC ANTIGEN RECEPTORS	08/25/2020	03/15/2023		PUBLISHED	08/24/2041
BLUE-131MX	Owned by Zseventy	MX	MX/a/2023/002373		BCMA CHIMERIC ANTIGEN RECEPTORS	08/25/2020	02/24/2023		PUBLISHED	08/24/2041
BLUE-131NZ	Owned by Zseventy	NZ	798288		BCMA CHIMERIC ANTIGEN RECEPTORS	08/25/2020	03/17/2023		PENDING	08/24/2041
BLUE-131P1	Owned by Zseventy	US	63/069784		BCMA CHIMERIC ANTIGEN RECEPTORS	08/25/2020	08/25/2020		CONV COMPLE	08/25/2021
BLUE-131PC	Owned by Zseventy	WO	PCT/US2021/047290	WO2022046730	BCMA CHIMERIC ANTIGEN RECEPTORS	08/25/2020	08/24/2021		COMPLETED	
BLUE-131SG	Owned by Zseventy	SG	11202301136P		BCMA CHIMERIC ANTIGEN RECEPTORS	08/25/2020	02/15/2023		ABANDONED	08/24/2041
BLUE-131SG2	Owned by Zseventy	SG	10202302193U		BCMA CHIMERIC ANTIGEN RECEPTORS	08/25/2020	08/01/2023		PENDING	
BLUE-131USPC	Owned by Zseventy	US	18/023232	US-2023-0310604-A1	BCMA CHIMERIC ANTIGEN RECEPTORS	08/25/2020	02/24/2023		PUBLISHED	
Zseventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-140AU	Owned by Zseventy	AU	2022310862.0		ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES	07/14/2021	07/14/2022		PENDING	
BLUE-140BR	Owned by Zseventy	BR	BR1120240004724		ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES	07/14/2021	07/14/2022		PENDING	
BLUE-140CA	Owned by Zseventy	CA	3225252.0		ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES	07/14/2021	07/14/2022		PENDING	

BLUE-140CN	Owned by 2seventy	CN			ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES	07/14/2021				TO BE FILED	
BLUE-140EP	Owned by 2seventy	EP	22768562.5		ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES	07/14/2021	07/14/2022			PENDING	
BLUE-140IL	Owned by 2seventy	IL	309957.0		ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES	07/14/2021	07/14/2022			PENDING	
BLUE-140JP	Owned by 2seventy	JP	2024-501757		ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES	07/14/2021	07/14/2022			PENDING	
BLUE-140KR	Owned by 2seventy	KR			ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES	07/14/2021				TO BE FILED	
BLUE-140P1	Owned by 2seventy	US	63/221819		T CELL RECEPTORS	07/14/2021	07/14/2021			CONV COMPLE	07/14/2022
BLUE-140PC	Owned by 2seventy	WO	PCT/US2022/073725	WO 2023/288267	ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES	07/14/2021	07/14/2022			PUBLISHED	
BLUE-140SG	Owned by 2seventy	SG	112024001790Q		ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES	07/14/2021	07/14/2022			PENDING	
BLUE-140USPC	Owned by 2seventy	US	18/578,367		ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES	07/14/2021	07/11/2024			PENDING	
2seventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date	
TSVT-001P1	Co-Owned 2seventy/SCRI	US	63/288468		METHOD AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A DIMERIZING AGENT REGULATED IMMUNOMODULATORY COMPLEX	12/10/2021	12/10/2021			EXPIRED	12/10/2022
TSVT-001PC	Co-Owned 2seventy/SCRI	WO	PCT/US2022/081322	WO2023108158	METHOD AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A DIMERIZING AGENT REGULATED IMMUNOMODULATORY COMPLEX	12/10/2021	12/09/2022			PENDING	
2seventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date	
TSVT-002P1	Co-Owned 2seventy/REGN	US	63/298141		MUC16 CHIMERIC ANTIGEN RECEPTORS	01/10/2022	01/10/2022			EXPIRED	01/10/2023
TSVT-002PC	Co-Owned 2seventy/REGN	WO	PCT/US2023/010518	WO 2023/133358	MUC16 CHIMERIC ANTIGEN RECEPTORS	01/10/2022	01/10/2023			PENDING	
2seventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date	
TSVT-003P1	Owned by 2seventy	US	63/329003		MULTIPARTITE RECEPTOR AND SIGNALING COMPLEXES	04/08/2022	04/08/2022			EXPIRED	04/08/2023
TSVT-003PC	Owned by 2seventy	WO	PCT/US2023/065553	WO2023196997	MULTIPARTITE RECEPTOR AND SIGNALING COMPLEXES	04/08/2022	04/07/2023			PENDING	
2seventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date	
TSVT-004P1	Owned by 2seventy	US	63/346001		COMPOSITIONS AND USES THEREOF	05/26/2022	05/26/2022			EXPIRED	05/26/2023
TSVT-004PC	Owned by 2seventy	WO	PCT/US2023/067406	WO2023230512	COMPOSITIONS AND USES THEREOF	05/26/2022	05/24/2023			PENDING	05/26/2023
2seventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date	
TSVT-005P1	Owned by 2seventy	US	63/329003		MULTIPARTITE RECEPTOR AND SIGNALING COMPLEXES	04/08/2022	04/08/2022			EXPIRED	04/08/2023
TSVT-005PC	Owned by 2seventy	WO	PCT/US2023/065552	WO2023196996	MULTIPARTITE RECEPTOR AND SIGNALING COMPLEXES	04/08/2022	04/07/2023			PENDING	
2seventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date	
TSVT-006P1	Co-Owned 2seventy/SCRI	US	63/499,467		CYTOKINE EXPRESSING ENGINEERED IMMUNE CELLS	05/01/2023	05/01/2023			PENDING	05/01/2013
TSVT-006P2	Co-Owned 2seventy/SCRI	US	63/502,875		CYTOKINE EXPRESSING ENGINEERED IMMUNE CELLS	05/17/2023	05/17/2023			PENDING	05/17/2023
2seventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date	
BLUE-040 AU	Co-Owned (Collectis/2seventy)	AU	2014273089.00	2014273089	A LADLIDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMOKINE RECEPTOR TYPE-5 (CCR5) GENE AND USES	05/31/2013	05/28/2014	06/07/2018		GRANTED	05/28/2034
BLUE-040 CA	Co-Owned (Collectis/2seventy)	CA	2913871.00	2,913,871	A LADLIDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMOKINE RECEPTOR TYPE-5 (CCR5) GENE AND USES	05/31/2013	05/28/2014			PENDING	
BLUE-040 DE	Co-Owned (Collectis/2seventy)	DE	14727480.00	3004149	A LADLIDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMOKINE RECEPTOR TYPE-5 (CCR5) GENE AND USES	05/31/2013	05/28/2014	12/29/2018		GRANTED	05/28/2034
BLUE-040 DK	Co-Owned (Collectis/2seventy)	DK	PA201370302		A LADLIDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMOKINE RECEPTOR TYPE-5 (CCR5) GENE AND USES	05/31/2013	05/31/2013			INACTIVE	
BLUE-040 EP	Co-Owned (Collectis/2seventy)	EP	14727480.00	3004149	A LADLIDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMOKINE RECEPTOR TYPE-5 (CCR5) GENE AND USES	05/31/2013	05/28/2014	12/29/2018		GRANTED	
BLUE-040 FR	Co-Owned (Collectis/2seventy)	FR	14727480.00	3004149	A LADLIDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMOKINE RECEPTOR TYPE-5 (CCR5) GENE AND USES	05/31/2013	05/28/2014	12/29/2018		GRANTED	05/28/2034
BLUE-040 GB	Co-Owned (Collectis/2seventy)	GB	14727480.00	3004149	A LADLIDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMOKINE RECEPTOR TYPE-5 (CCR5) GENE AND USES	05/31/2013	05/28/2014	12/29/2018		GRANTED	05/27/2034
BLUE-040 HK	Co-Owned (Collectis/2seventy)	HK	16111488.00	1223394	A LADLIDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMOKINE RECEPTOR TYPE-5 (CCR5) GENE AND USES	05/31/2013	05/28/2014	09/27/2019		GRANTED	05/28/2034
BLUE-040 JP	Co-Owned (Collectis/2seventy)	JP	2016516171.00	6488283	A LADLIDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMOKINE RECEPTOR TYPE-5 (CCR5) GENE AND USES	05/31/2013	05/28/2014	03/01/2019		GRANTED	05/28/2034
BLUE-040 PC	Co-Owned (Collectis/2seventy)	WO	PCT/EP2014/0611186	2014191525	A LADLIDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMOKINE RECEPTOR TYPE-5 (CCR5) GENE AND USES	05/31/2013	05/28/2014			INACTIVE	
BLUE-040 USPC	Co-Owned (Collectis/2seventy)	US	14/891,202	10,006,052	A LADLIDADG HOMING ENDONUCLEASE CLEAVING THE CC CHEMOKINE RECEPTOR TYPE-5 (CCR5) GENE AND USES	05/31/2013	05/28/2014	06/26/2018		GRANTED	05/28/2034
2seventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date	
BLUE-044 AU	Co-Owned (Collectis/2seventy)	AU	2014273091.00	2014273091	A LADLIDADG HOMING ENDONUCLEASE CLEAVING THE TCRA GENE AND USES	05/31/2013	05/28/2014	03/26/2020		GRANTED	05/28/2034
BLUE-044 CA	Co-Owned (Collectis/2seventy)	CA	2913872.00	2,913,872	A LADLIDADG HOMING ENDONUCLEASE CLEAVING THE TCRA GENE AND USES	05/31/2013	05/28/2014			PENDING	
BLUE-044 CH	Co-Owned (Collectis/2seventy)	CH	14728899.00	3004338	A LADLIDADG HOMING ENDONUCLEASE CLEAVING THE TCRA GENE AND USES	05/31/2013	05/28/2014	01/02/2019		GRANTED	05/28/2034
BLUE-044 DE	Co-Owned (Collectis/2seventy)	DE	14728899.00	3004338	A LADLIDADG HOMING ENDONUCLEASE CLEAVING THE TCRA GENE AND USES	05/31/2013	05/28/2014	01/02/2019		GRANTED	05/28/2034
BLUE-044 DK	Co-Owned (Collectis/2seventy)	DK	PA201370303		A LADLIDADG HOMING ENDONUCLEASE CLEAVING THE TCRA GENE AND USES	05/31/2013	05/31/2013			INACTIVE	
BLUE-044 DK2	Co-Owned (Collectis/2seventy)	DK	14728899.00	3004338	A LADLIDADG HOMING ENDONUCLEASE CLEAVING THE TCRA GENE AND USES	05/31/2013	05/28/2014	01/02/2019		GRANTED	05/28/2034
BLUE-044 EP	Co-Owned (Collectis/2seventy)	EP	14728899.00	3004338	A LADLIDADG HOMING ENDONUCLEASE CLEAVING THE TCRA GENE AND USES	05/31/2013	05/28/2014	01/02/2019		GRANTED	05/28/2034
BLUE-044 ES	Co-Owned (Collectis/2seventy)	ES	14728899.00	3004338	A LADLIDADG HOMING ENDONUCLEASE CLEAVING THE TCRA GENE AND USES	05/31/2013	05/28/2014	01/02/2019		GRANTED	05/28/2034
BLUE-044 FR	Co-Owned (Collectis/2seventy)	FR	14728899.00	3004338	A LADLIDADG HOMING ENDONUCLEASE CLEAVING THE TCRA GENE AND USES	05/31/2013	05/28/2014	01/02/2019		GRANTED	05/28/2034
BLUE-044 GB	Co-Owned (Collectis/2seventy)	GB	14728899.00	3004338	A LADLIDADG HOMING ENDONUCLEASE CLEAVING THE TCRA GENE AND USES	05/31/2013	05/28/2014	01/02/2019		GRANTED	05/27/2034
BLUE-044 HK	Co-Owned (Collectis/2seventy)	HK	16111487.00	1223373	A LADLIDADG HOMING ENDONUCLEASE CLEAVING THE TCRA GENE AND USES	05/31/2013	05/28/2014	09/27/2019		GRANTED	05/28/2034
BLUE-044 IT	Co-Owned (Collectis/2seventy)	IT	14728899.00	3004338	A LADLIDADG HOMING ENDONUCLEASE CLEAVING THE TCRA GENE AND USES	05/31/2013	05/28/2014	01/02/2019		GRANTED	05/28/2034
BLUE-044 JP	Co-Owned (Collectis/2seventy)	JP	2016516173.00	6450371	A LADLIDADG HOMING ENDONUCLEASE CLEAVING THE TCRA GENE AND USES	05/31/2013	05/28/2014	01/09/2019		GRANTED	05/28/2034
BLUE-044 NL	Co-Owned (Collectis/2seventy)	NL	14728899.00	3004338	A LADLIDADG HOMING ENDONUCLEASE CLEAVING THE TCRA GENE AND USES	05/31/2013	05/28/2014	01/02/2019		GRANTED	05/28/2034
BLUE-044 PC	Co-Owned (Collectis/2seventy)	WO	PCT/EP2014/0611189	2014191527	A LADLIDADG HOMING ENDONUCLEASE CLEAVING THE TCRA GENE AND USES	05/31/2013	05/28/2014			INACTIVE	
BLUE-044 USPC	Co-Owned (Collectis/2seventy)	US	14/891,216	10,000,746	A LADLIDADG HOMING ENDONUCLEASE CLEAVING THE TCRA GENE AND USES	05/31/2013	05/28/2014	06/19/2018		GRANTED	05/28/2034
2seventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date	
BLUE-076 AU	Owned by 2seventy	AU	2017323629		PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	09/08/2016	09/08/2017	06/29/2023		GRANTED	09/08/2037
BLUE-076 BR	Owned by 2seventy	BR	BR1120190046291		PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	09/08/2016	09/08/2017			PENDING	
BLUE-076 C1	Owned by 2seventy	US	17/738,484	US-2022-0340626-A1	PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	09/08/2016	05/06/2022			ALLOWED	
BLUE-076 CA	Owned by 2seventy	CA	3035455		PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	09/08/2016	09/08/2017			PUBLISHED	
BLUE-076 CN	Owned by 2seventy	CN	201780065641.7	109923211	PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	09/08/2016	09/08/2017			PUBLISHED	
BLUE-076 EP	Owned by 2seventy	EP	17849655.0	3510157	PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	09/08/2016	09/08/2017	05/31/2023		GRANTED	09/08/2037
BLUE-076 EP2	Owned by 2seventy	EP	23173344.5	4248979	PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	09/08/2016	05/15/2023			PUBLISHED	
BLUE-076 HK	Owned by 2seventy	HK	19128724.2	40005329	PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	09/08/2016	08/26/2019	08/04/2023		GRANTED	09/08/2037
BLUE-076 ID	Owned by 2seventy	ID	PID021902924	2019/07655	PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	09/08/2016	09/08/2017	03/08/2023		GRANTED	09/08/2037
BLUE-076 IL	Owned by 2seventy	IL	265045		PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	09/08/2016	09/08/2017	08/02/2023		GRANTED	09/08/2037
BLUE-076 IN	Owned by 2seventy	IN	201917013007	201917013007	PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	09/08/2016	09/08/2017			PUBLISHED	
BLUE-076 JP	Owned by 2seventy	JP	2019-512872	2019-526268	PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	09/08/2016	09/08/2017	09/26/2023		GRANTED	09/08/2037
BLUE-076 JP2	Owned by 2seventy	JP	2023-119149	2023-126653	PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	09/08/2016	07/21/2023			PUBLISHED	
BLUE-076 KR	Owned by 2seventy	KR	10-2019-7009497	10-2019-0045928	PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	09/08/2016	09/08/2017	09/30/2022		GRANTED	09/08/2037
BLUE-076 KR2	Owned by 2seventy	KR	10-2022-7034173	10-2022-0140017	PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	09/08/2016	09/30/2022			ALLOWED	
BLUE-076 MX	Owned by 2seventy	MX	MX/a/2019/002725	MX/a/2019/002725	PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	09/08/2016	09/08/2017			PUBLISHED	
BLUE-076 NZ	Owned by 2seventy	NZ	751189		PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	09/08/2016	09/08/2017			PENDING	
BLUE-076 P1	Owned by 2seventy	US	62/385,079		PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	09/08/2016	09/08/2016			INACTIVE	
BLUE-076 P2	Owned by 2seventy	US	62/414,279		PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	10/28/2016	10/28/2016			INACTIVE	
BLUE-076 PC	Owned by 2seventy	WO	PCT/US2017/050774	2018049226	PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	09/08/2016	09/08/2017			INACTIVE	
BLUE-076 RU	Owned by 2seventy	RU	2019110065		PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	09/08/2016	09/08/2017	09/08/2022		GRANTED	09/08/2037

BLUE-076.SG	Owned by 2seventy	SG	11201901757Y		PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	09/08/2016	09/08/2017		PENDING	
BLUE-076.USPC	Owned by 2seventy	US	16/330,039	US-2021-0040165-A1	PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	09/08/2016	03/01/2019	06/21/2022	GRANTED	09/22/2038
BLUE-076.ZA	Owned by 2seventy	ZA	2019/01384		PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	09/08/2016	09/08/2017		PENDING	
Zseventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-077.AU	Owned by 2seventy	AU	2017342273		TCRa HOMING ENDONUCLEASE VARIANTS	10/11/2016	10/11/2017	10/19/2023	GRANTED	10/11/2037
BLUE-077.C1	Owned by 2seventy	US	18/174,165	US-2023-0357736-A1	TCRa HOMING ENDONUCLEASE VARIANTS	10/11/2016	02/24/2023		PUBLISHED	
BLUE-077.CN	Owned by 2seventy	CN	201780074992.4	110036107A	TCRa HOMING ENDONUCLEASE VARIANTS	10/11/2016	10/11/2017		PUBLISHED	
BLUE-077.EP	Owned by 2seventy	EP	17859441.2	3534916	TCRa HOMING ENDONUCLEASE VARIANTS	10/11/2016	10/11/2017		PUBLISHED	
BLUE-077.HK	Owned by 2seventy	HK	62020002320.3	40012926	TCRa HOMING ENDONUCLEASE VARIANTS	10/11/2016	06/02/2020		PUBLISHED	
BLUE-077.JP	Owned by 2seventy	JP	2019-540313	2019-532674	TCRa HOMING ENDONUCLEASE VARIANTS	10/11/2016	10/11/2017	06/12/2022	GRANTED	10/11/2037
BLUE-077.P1	Owned by 2seventy	US	62/406,589		TCRa HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	10/11/2016	10/11/2016		INACTIVE	
BLUE-077.P2	Owned by 2seventy	US	62/414,266		TCRa HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	10/28/2016	10/28/2016		INACTIVE	
BLUE-077.PC	Owned by 2seventy	WO	PCT/US2017/056178	2018071565	TCRa HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	10/11/2016	10/11/2017		INACTIVE	
BLUE-077.USPC	Owned by 2seventy	US	16/340,257	US-2022-0186198-A1	TCRa HOMING ENDONUCLEASE VARIANTS	10/11/2016	04/08/2019	02/28/2023	GRANTED	06/30/2040
Zseventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-078.AU	Owned by 2seventy	AU	2017346683		TGFBetaR2 ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	10/17/2016	10/17/2017		PENDING	
BLUE-078.CA	Owned by 2seventy	CA	3040157	3040157	TGFBetaR2 ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	10/17/2016	10/17/2017		PUBLISHED	
BLUE-078.CN	Owned by 2seventy	CN	201780076229.5	110050066	TGFBetaR2 ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	10/17/2016	10/17/2017		PUBLISHED	
BLUE-078.EP	Owned by 2seventy	EP	17861537.3	3526334	TGFBetaR2 ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	10/17/2016	10/17/2017		PUBLISHED	
BLUE-078.JP	Owned by 2seventy	JP	2019-520527	2019-535240	TGFBetaR2 ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	10/17/2016	10/17/2017	04/18/2022	GRANTED	10/17/2037
BLUE-078.P1	Owned by 2seventy	US	62/409,163		TGFB2 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	10/17/2016	10/17/2016		INACTIVE	
BLUE-078.P2	Owned by 2seventy	US	62/414,260		TGFB2 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	10/28/2016	10/28/2016		INACTIVE	
BLUE-078.PC	Owned by 2seventy	WO	PCT/US2017/057014	2018075541	TGFB2 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	10/17/2016	10/17/2017		INACTIVE	
BLUE-078.USPC	Owned by 2seventy	US	16/341,228	US-2020-0123515	TGFBetaR2 ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	10/17/2016	04/11/2019	12/20/2022	GRANTED	01/08/2040
Zseventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-087.AU	Owned by 2seventy	AU	2018273979		CBLL ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	05/25/2017	05/25/2018		PENDING	
BLUE-087.C1	Owned by 2seventy	US	16/694,815	US-2020-0087653	CBLL ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	05/25/2017	11/25/2019	02/23/2021	GRANTED	05/25/2038
BLUE-087.C2	Owned by 2seventy	US	16/694,810	US 2020-0109385	CBLL ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	05/25/2017	11/25/2019	10/06/2020	GRANTED	10/04/2038
BLUE-087.C3	Owned by 2seventy	US	17/150,533	US 2021-0214700	CBLL ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	05/25/2017	01/15/2021		PUBLISHED	
BLUE-087.CA	Owned by 2seventy	CA	3064014	3064014	CBLL ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	05/25/2017	05/25/2018		PUBLISHED	
BLUE-087.CN	Owned by 2seventy	CN	201880042211.8	CN110799644A	CBLL ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	05/25/2017	05/25/2018		PUBLISHED	
BLUE-087.D1	Owned by 2seventy	US	17/150,293	US 2021-0214714 A1	CBLL ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	05/25/2017	01/15/2021	08/22/2023	GRANTED	09/16/2038
BLUE-087.EP	Owned by 2seventy	EP	18806825.8	3630962	CBLL ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	05/25/2017	05/25/2018		PUBLISHED	
BLUE-087.HK	Owned by 2seventy	HK	62020015146.7	40025461	CBLL ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	05/25/2017	08/07/2020		PUBLISHED	
BLUE-087.IL	Owned by 2seventy	IL	270776		CBLL ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	05/25/2017	05/25/2018		PENDING	
BLUE-087.JP	Owned by 2seventy	JP	2019-564937	2020-521456	CBLL ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	05/25/2017	05/25/2018	12/08/2022	GRANTED	05/25/2038
BLUE-087.JP2	Owned by 2seventy	JP	2022-166786	2022-183262	CBLL ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	05/25/2017	10/18/2022		PUBLISHED	
BLUE-087.KR	Owned by 2seventy	KR	10-2019-7036681	10-2020-0011953	CBLL ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	05/25/2017	05/25/2018	10/12/2023	GRANTED	05/25/2038
BLUE-087.KR2	Owned by 2seventy	KR	10-2023-7034961	10-2023-0147767	CBLL ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	05/25/2017	10/12/2023		PUBLISHED	
BLUE-087.MX	Owned by 2seventy	MX	MX/a/2019/014100		CBLL ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	05/25/2017	05/25/2018		PENDING	
BLUE-087.NZ	Owned by 2seventy	NZ	759382		CBLL ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	05/25/2017	05/25/2018		PENDING	
BLUE-087.RU	Owned by 2seventy	RU	2019141853		CBLL ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	05/25/2017	05/25/2018	08/31/2022	GRANTED	05/25/2038
BLUE-087.SG	Owned by 2seventy	SG	11201910796Y		CBLL ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	05/25/2017	05/25/2018		PENDING	
BLUE-087.P1	Owned by 2seventy	US	62/511,194		CBLL ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	05/25/2017	05/25/2017		INACTIVE	
BLUE-087.P2	Owned by 2seventy	US	62/567,417		CBLL ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	10/03/2017	10/03/2017		INACTIVE	
BLUE-087.PC	Owned by 2seventy	WO	PCT/US2018/034726	2018218194	CBLL ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	05/25/2017	05/25/2018		INACTIVE	
BLUE-087.PC2	Owned by 2seventy	WO	PCT/US2018/054347	2020072059	CBLL ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	10/04/2018	10/04/2018		INACTIVE	
BLUE-087.USPC	Owned by 2seventy	US	16/616,713	US-2021-0147818	CBLL ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE	05/25/2017	11/25/2019		PUBLISHED	
Zseventy Ref.	RIGHTS	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-109.AU	Owned by 2seventy	AU	2019395334		PCDC-1 HOMING ENDONUCLEASE VARIANTS	12/10/2018	12/09/2019		PENDING	
BLUE-109.CA	Owned by 2seventy	CA	3122094	3122094	PCDC-1 HOMING ENDONUCLEASE VARIANTS	12/10/2018	12/09/2019		PUBLISHED	
BLUE-109.CN	Owned by 2seventy	CN	201980090012.9	113330113	PCDC-1 HOMING ENDONUCLEASE VARIANTS	12/10/2018	12/09/2019		PUBLISHED	
BLUE-109.EP	Owned by 2seventy	EP	19897267.1	3893886	PCDC-1 HOMING ENDONUCLEASE VARIANTS	12/10/2018	12/09/2019		PUBLISHED	
BLUE-109.HK	Owned by 2seventy	HK	62022051747.3	40062294	PCDC-1 HOMING ENDONUCLEASE VARIANTS	12/10/2018	04/14/2022		PUBLISHED	
BLUE-109.IL	Owned by 2seventy	IL	283724		PCDC-1 HOMING ENDONUCLEASE VARIANTS	12/10/2018	12/09/2019		PENDING	
BLUE-109.JP	Owned by 2seventy	JP	2021-532869	2022-510481	PCDC-1 HOMING ENDONUCLEASE VARIANTS	12/10/2018	12/09/2019		PUBLISHED	
BLUE-109.KR	Owned by 2seventy	KR	10-2021-7020809	10-2021-0102299	PCDC-1 HOMING ENDONUCLEASE VARIANTS	12/10/2018	12/09/2019		PUBLISHED	
BLUE-109.P1	Owned by 2seventy	US	62/777,471		PCDC-1 HOMING ENDONUCLEASE VARIANTS	12/10/2018	12/10/2018		INACTIVE	
BLUE-109.PC	Owned by 2seventy	WO	PCT/US2019/065223	2020123375	PCDC-1 HOMING ENDONUCLEASE VARIANTS	12/10/2018	12/09/2019		INACTIVE	
BLUE-109.USPC	Owned by 2seventy	US	17/311,455	US-2022-0177860-A1	PCDC-1 HOMING ENDONUCLEASE VARIANTS	12/10/2018	06/07/2021		PUBLISHED	

ASSIGNMENT

WHEREAS, I, **David DILILLO**, residing at 351 East 84th Street, Apartment 15F, New York, New York 10028, a citizen of the United States of America, made certain new and useful inventions and improvements for which I filed international application No. **PCT/US2023/010518**, on January 10, 2023, designating the United States of America, which is entitled **MUC16 CHIMERIC ANTIGEN RECEPTORS** and claiming priority to Provisional Application 63/298,141, filed January 10, 2022.

AND WHEREAS, **Regeneron Pharmaceuticals, Inc.**, a corporation organized and existing under and by virtue of the laws of the State of New York, and having an office and place of business at 777 Old Saw Mill River Road, Tarrytown, New York 10591 (hereinafter "Assignee") is desirous of acquiring the entire right, title and interest in and to said inventions, improvements and application and in and to the Letters Patent to be obtained therefor;


NOW THEREFORE, to all whom it may concern, be it known that for good and valuable considerations, the receipt and sufficiency whereof is hereby acknowledged, I have sold, assigned, and transferred, and by these presents do sell, assign and transfer unto said Assignee, its successors or assigns, the entire right, title and interest for all countries in and to all inventions and improvements disclosed in the aforesaid application, and in and to the application, all divisions, continuations, or renewals thereof, all Letters Patent which may be granted therefrom, and all reissues or extensions of such patents, and all applications for industrial property protection, including, without limitation, all applications for patents utility models, and designs, and in and to any and all applications which have been or shall be filed in any country or countries for Letters Patent on the inventions and improvements, including an assignment of all rights under the provisions of the International Convention of 1883 and later modifications thereof, under the Patent Cooperation Treaty, under the European Patent Convention, or under any other available international agreement or under the domestic laws of the country in which any such application is filed, as may be applicable, and all Letters Patent of a country or countries which may be granted therefrom; and I do hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any Official of any country or countries foreign to the United States whose duty it is to issue patents or other evidence or forms of industrial property protection on applications as aforesaid, to issue the same to the Assignee as the assignee of the entire right, title and interest in and to the same, for the use of the Assignee, its successors and assigns;

AND, for the consideration aforesaid, I do hereby agree that I and our executors and legal representatives will make, execute and deliver any and all other instruments in writing including any and all further application papers, affidavits, assignments and other documents, and will communicate to said Assignee, its successors and representatives all facts known to us relating to said improvements and the history thereof and will testify in all legal proceedings and generally do all things which may be necessary or desirable more effectually to secure to and vest in said Assignee, its successors or assigns the entire right, title and interest in and to the improvements, inventions, applications, Letters Patent, rights, titles, benefits, privileges and advantages hereby sold, assigned and conveyed, or intended so to be;

AND, furthermore I covenant and agree with said Assignee, its successors and assigns, that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by us and that full right to convey the same as herein expressed is possessed by us.

REGN Ref. No.: 11250WO01
Application No.: PCT/US2023/010518

IN TESTIMONY WHEREOF, I have hereunto set my hand this 10 day of NOVEMBER, 2023.
DAY MONTH


David DILLILLO